You are here

INC424

Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting

Yahoo/BusinessWire

Sun, 06/5/11 - 10:03 am

Novartis maps out a blockbuster future for INC424

Fierce Biotech

Wed, 03/16/11 - 09:21 am